Is Buying Stock Like Arbutus Biopharma Corporation (ABUS) After Such Increase Winning Strategy?

March 22, 2018 - By Maria Brooks

The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) is a huge mover today! The stock increased 7.95% or $0.35 during the last trading session, reaching $4.75. About 269,273 shares traded or 54.14% up from the average. Arbutus Biopharma Corporation (NASDAQ:ABUS) has declined 2.31% since March 22, 2017 and is downtrending. It has underperformed by 19.01% the S&P500.
The move comes after 8 months positive chart setup for the $261.58 million company. It was reported on Mar, 22 by We have $4.94 PT which if reached, will make NASDAQ:ABUS worth $10.46 million more.

Arbutus Biopharma Corporation (NASDAQ:ABUS) Ratings Coverage

Among 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Arbutus Biopharma had 16 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was downgraded by Chardan Capital Markets to “Sell” on Friday, July 8. The firm has “Neutral” rating by Chardan Capital Markets given on Thursday, June 16. The rating was maintained by Leerink Swann on Tuesday, November 7 with “Market Perform”. The rating was upgraded by Chardan Capital Markets on Wednesday, November 30 to “Buy”. The rating was initiated by Wedbush with “Outperform” on Friday, August 7. The firm earned “Buy” rating on Friday, August 4 by Chardan Capital Markets. The rating was downgraded by Leerink Swann on Friday, August 5 to “Market Perform”. The rating was downgraded by Chardan Capital Markets on Tuesday, December 13 to “Neutral”. The firm has “Outperform” rating by Wedbush given on Friday, August 7. The stock of Arbutus Biopharma Corporation (NASDAQ:ABUS) has “Sell” rating given on Monday, May 16 by Chardan Capital Markets.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B virus infection in Canada and the United States. The company has market cap of $261.58 million. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). It currently has negative earnings. The company's lead candidate is ARB-1467, which is in a Phase II trial to eliminate HBV surface antigen expression in patients chronically infected with HBV.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.